Patients and methods: Patients with a histologically confirmed HNSCC with metastasis or recurrence unsuitable for locoregional curative treatment received docetaxel and cisplatin (75 mg/m 2 both) at day 1 and weekly cetuximab 250 mg/m 2 (loading dose of 400 mg/m 2 ), repeated every 21 days for four cycles, followed by maintenance cetuximab 500 mg/m 2 every 2 weeks until progression or unacceptable toxicity. Prophylactic administration of granulocyte colony-stimulating factor was done systematically after each chemotherapy cycle. Patients had a good general status ( performance status ≤1) and were under 71 years. Prior total doses of cisplatin exceeding 300 mg/m 2 were not allowed. The primary end point was objective response rate (ORR) after four cycles.
Results: Fifty-four patients were enrolled. The primary end point was met with an ORR of 44.4% (95% CI 30.9-58.6).
Median overall and progression-free survivals were, respectively, 14 months (95% CI 11.3-17.3) and 6.2 months (95% CI 5.4-7.2). The most common grade 3/4 adverse events were skin rash (16.6%) and non-febrile neutropenia (20.4%). There were one pulmonary embolism and two infectious events leading to death.
Conclusions:
The TPEx regimen showed promising activity as first-line treatment in fit patients with recurrent/metastatic HNSCC. Further studies are needed to compare the TPEx versus EXTREME regimen in this population.
ClinicalTrial.gov: NCT01289522.
Key words: head and neck cancer, docetaxel, cetuximab, chemotherapy, maintenance, first line introduction Locoregional recurrence of head and neck squamous cell carcinoma (HNSCC) occurs in up to 50% of patients who responded to combined-modality treatment, and ∼25% of all patients develop distant metastases. For patients with recurrent disease ineligible for locoregional curative treatment, prognosis is very poor with median survival of 6-10 months with optimal systemic treatment [1] [2] [3] [4] [5] .
The goals of treatment in this setting are thus to delay progression and prolong survival while maintaining quality of life [3] . For most patients, palliative chemotherapy is the standard option. However, fit patients with aggressive symptomatic disease should be considered for platinum-based, multiagent regimens that combine cytotoxic chemotherapy with cetuximab [4] . Three phase III randomized, clinical trials have shown that addition of anti-epidermal growth factor receptor (EGFR) monoclonal antibodies to chemotherapy improves clinical outcomes in this population [1, 5, 6] . The EXTREME regimen [ platinum, 5-fluorouracil (5-FU), and cetuximab] was the first to demonstrate a significant improvement in overall survival (OS) at 10.1 months following the introduction of cisplatin in the 1970s [5] , and is currently considered the first-line standard option for this population with a level of evidence and grade of recommendation of IIA [7] . However, long-term survival remains disappointing.
In this context, other therapeutic approaches have been tested, but have failed to demonstrate significant improvement [6, [8] [9] [10] .
Preclinical data have suggested a synergistic effect of taxanes and cetuximab [11] , which is currently unexplained. The combination of taxanes with cetuximab or platinum specifically showed interesting antitumor efficacy in phase II trials [12] [13] [14] [15] [16] [17] , in particular in relation to docetaxel with cisplatin. This combination also presents the advantage of being easier to deliver in daily practice and of having fewer contraindications than the standard 5-FU-cisplatin combination used in the EXTREME regimen.
The GORTEC 2008-03 TPEx study is a phase II trial evaluating four cycles of docetaxel in combination with cisplatin and cetuximab (termed TPEx) as first-line treatment of recurrent and/or metastatic HNSCC. We hypothesized that the docetaxelplatinum combination, already used as a standard in lung cancer [18] , followed by a cetuximab maintenance phase administered every 2 weeks as in colorectal cancer [19] , would have a favorable benefit-to-risk ratio. We report here the efficacy and safety results of the regimen. The primary end point was the objective response rate (ORR). The primary end point was the ORR, defined as a complete or partial response after four treatment cycles by an investigator review. Secondary end points were best overall response, progression-free survival (PFS), OS, and safety.
patients and methods

study design
patient population
For inclusion in the study, patients were required to be aged 18-70 years and to have histologically confirmed cancer of the oral cavity, oropharynx, hypopharynx, or larynx with a metastasis or recurrence not relevant for locoregional curative treatment, a World Health Organization performance status (PS) of ≤1.
Key exclusion criteria were: prior systemic chemotherapy for HNSCC (except if administered as part of a multimodal treatment for locally advanced disease >6 months before study entry); prior dose of cisplatin >300 mg/m 2 ; contraindication to cisplatin; and previous treatment with EGFR-targeting therapy or signal transduction inhibitors. Written informed consent was obtained before any study procedure. Complete eligibility criteria are given in supplementary Materials, available at Annals of Oncology online. Study design and dose modifications are described in supplementary Figure S1 , available at Annals of Oncology online and supplementary Materials, available at Annals of Oncology online.
treatment plan
study assessments
Baseline assessments included a complete medical history, a clinical and physical examination, an electrocardiogram, complete blood count, blood chemistry tests, and a CT scan or MRI of the neck and chest. Imaging within 4 weeks post-screening was considered acceptable. Patients were assessed weekly during TPEx and every 2 weeks during maintenance. After disease progression, survival status and any further anticancer treatments were documented.
response assessments
The tumor response was assessed by the CT scan or MRI at 6-week intervals after the start of treatment. Best response evaluated by RECIST 1.0 criteria was recorded until disease progression. All imaging assessments were reviewed by at least one investigator and one radiologist at each center.
determination of human papilloma virus for oropharynx tumor
Tumoral tissues were obtained from oropharyngeal cancer patients at baseline for p16 status. Formalin-fixed, paraffin-embedded tissue sections were evaluated locally by in situ hybridization for human papilloma virus (HPV) nucleic acids. Tumor p16 expression was detected with concurrent positive and negative controls.
statistical methods
The primary objective was to determine the ORR, defined as a complete (CR) or partial response (PR) after four chemotherapy cycles corresponding to 12 weeks (W12). The secondary objectives were to evaluate OS, the best overall response [CR, PR, or stable disease (SD) persisting for at least 6 weeks from treatment start to progression/recurrence], PFS, disease control (defined as the sum of CR, PR, and SD), and safety.
The Simon's two-stage optimal design for phase II clinical trials was used. The null hypothesis that the true response rate is ≤0.30 was tested against a one-sided alternative that the true response rate is ≥0.50. In the first stage, 30 patients had to be accrued. If there were nine or fewer responses (CR + PR at W12) in these 30 patients, the study should be stopped. Otherwise, 24 additional patients should be accrued for a total of 54. The null hypothesis was rejected if 21 or more responses (CR + PR at W12) were observed in 54 patients. In this design, the type 1 error rate was 0.095 and the type 2 error rate was 0.049.
Additional details on methodology are published in supplementary Material, available at Annals of Oncology online. results patients Fifty-four patients were enrolled between September 2009 and February 2011. Toxicity and survival were assessed in all 54 patients, whereas response was assessed at W12 in 48 patients. Patients characteristics are summarized in Table 1 : patients were predominantly males (96.0%) and most had a PS of 1 (74.1%). Oral cavity was the primary tumor site in one-third of patients. Three of the 12 oropharyngeal carcinomas were HPV-positive. More than 40.0% had previously received cisplatin and most patients were metastatic (70.4%). More than half of the patients were smokers, with a median of 41.5 pack-years and ∼45.0% reported regular use of alcohol. Medical nutritional support was necessary in only 14.8% of patients with 3 using a nasogastric tube and 5 a gastrostomy.
treatment
During the TPEx regimen, a total of 202 cycles were administered (median four cycles; mean 3.7 ± 0.7 cycles/patient; supplementary Table S1 , available at Annals of Oncology online). The dose-intensity calculation demonstrated the generally good tolerance of the treatment, with >85.0% of the patients receiving the planned four cycles of TPEx and a relative dose intensity of the cytotoxics above 98.0%. The cetuximab dose intensity was 84.6% ± 9.9%. Forty-three patients with disease control (79.6%) were able to start the maintenance phase. During this phase, the median relative dose intensity of cetuximab was close to 100%, with a median of seven doses per patient. The mean duration of the maintenance phase was 4.6 ± 4.5 months. One patient was treated with cetuximab during maintenance for >22 months. No patient was lost to follow-up.
responses
The primary end point was reached with an ORR at W12 of 44.4% (95% CI 30.9-58.6; Table 2 ). In the intention-to-treat (ITT) population, 44.4% (24/54 patients) had a PR confirmed 6 weeks later (week 18), and nearly 35% had confirmed SD (19/ 54), amounting to almost 80% of patients with a controlled disease after four cycles of TPEx regimen. Five patients had progressive disease. Six patients could not be evaluated at W12 due to toxicities leading to treatment discontinuation (cetuximab hypersensitivity and ototoxicity) and four deaths. Results in patients with assessable response at W12 are illustrated in supplementary Table S2 , available at Annals of Oncology online (N = 48). The best overall ORR taking into account only confirmed responses obtained during the TPEx regimen and maintenance was 51.9% (28/54 patients). One patient with distant metastasis at diagnosis presented a CR during maintenance.
Of note, a response to treatment was obtained early in 20 patients, with an ORR of 37% at 6 weeks. Responses were confirmed at W12 (supplementary Figure S2 , available at Annals of Oncology online). Exploratory analysis of the subgroups of previously irradiated patients or metastatic patients revealed no statistical differences in terms of response compared with non-irradiated patients or patients with locoregional recurrence alone (supplementary Tables S3 and S4, available at Annals of Oncology online).
follow-up anticancer treatment
Forty-one of the 43 patients received anticancer treatment after the maintenance phase, as 2 patients died toward the end of the maintenance phase. Second-line therapy consisted mostly of chemotherapy (87.8%) during the first 12 months. Monoclonal antibodies accounted for ∼20% of therapy delivered between 12 and 18 months after the end of cetuximab maintenance, along with chemotherapy (65%), surgery and other treatments (15%).
toxicity
The safety profile of the study treatment was consistent with that expected for the agents used and with the agents' high dose intensity observed: 56.6% grade 1 and 34.6% grade 2 with a mean of 4 events/patients (mainly skin/ungeal toxicities, oral mucositis, and gastrointestinal disorders; Table 3 ). Alopecia was common. Only 10% of grade 3/4 events were observed and consisted mainly of cetuximab-induced skin toxicity, neutropenia, and infections. Ten patients only experienced neutropenia grade 3/4 without complication or febrile neutropenia, including 5 had not received GCSF support before the event (9.3%). Only few patients experienced grade 4 adverse events (N = 12). No grade 4 febrile neutropenia was noted. Most of the deaths were cancer-related, except one that was caused by a pulmonary embolism within 2 weeks following the first cycle, one following a sepsis on gastrostomy tube and the last that was caused by pneumonia. One death was considered by the investigators to be treatment-related. Adverse events led to chemotherapy or cetuximab discontinuation in 9.2% of patients.
survival
After a median observation period of 14 months, 52 OS and 43 PFS events occurred in the ITT population (Figure 1 ). Median OS Interesting survival rates were observed in the population of patients able to start maintenance treatment (N = 43): OS rates at 12 and 24 months were, respectively, 69.8% (95% CI 53.7-81.2) and 25.6% (95% CI 13.8-39.1). Similarly, median survivals were higher: median OS = 16.8 months (95% CI 13.3-20.4) and median PFS = 7.1 months (95% CI 5.8-8.4).
discussion
The aim of this phase II study was to assess the efficacy and safety of the TPEx regimen in patients with recurrent/metastatic HNSCC. The primary end point was met: the results confirmed the combination's antitumor activity at W12 with an ORR of 44.4% and a best overall ORR of 51.9% in the ITT population. Survivals were also promising with median OS and PFS of 14.0 and 6.2 months, increasing to, respectively, 16.8 and 7.1 months in the population of patients with disease control after TPEx regimen.
Few recent studies have investigated first-line treatment for recurrent/metastatic HNSCC [6, 9, 10, 15] . Our results are somewhat higher in terms of response and survival than those consistently reported in the SPECTRUM [6] , ADVANTAGE [10] , and CeFCiD [20] studies, as well as for the standard EXTREME regimen [5] .
However, even if it is risky to compare phase II with phase III data, some assumptions can be made to explain them, in addition to the known synergistic effect of taxanes and cetuximab.
The first one relates to the high relative dose intensity observed for each agent, which may contribute directly to a better disease control and a significant proportion of patients able to start maintenance (79.6%). The absence of 5-FU as well as the fact that TPEx regimen comprises four cycles instead of six may favor a better tolerance, despite the reduced cisplatin total dose.
A generally manageable safety profile with fewer treatmentrelated dose reductions, discontinuations, and fatal events could also explain a greater chance to withstand subsequent chemotherapy and prolonged survival.
A new cetuximab maintenance scheme at the dose of 500 mg/m 2 every 2 weeks and differences in follow-up anticancer treatment may all have played a role, but these potential reasons are speculative. Second, good general health status patients were selected to be able to receive cisplatin without the possibility to switch to carboplatin in the event of toxicity. This could have an impact on longer survival reported in the EXTREME regimen. However, we can also argue that the SPECTRUM and ADVANTAGE patients were similar to ours [6, 10] , but demonstrated inferior results for ORR, OS, and PFS in the control arm. Our results were also confirmed by the retrospective series of Even et al. [21] , in which no attempt was made to select the population treated by TPEx. Finally, the characteristics of our patients regarding HPV status and previous chemotherapy were of lower prognosis.
In conclusion, we demonstrated that four cycles of docetaxel combined with cisplatin and cetuximab followed by maintenance cetuximab were feasible, convenient and precociously active with a manageable safety profile in fit patients with recurrent/metastatic HNSCC.
The European TPExtreme study comparing the TPEx and EXTREME regimens is currently ongoing and will contribute to determining the benefits of TPEx as first-line treatment in this population (ClinicalTrial.gov no. NCT02268695).
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